Razwanur Rahman Tushar
Research Subjects
Razwanur Rahman Tushar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Arif Hossin
Pharmacy Discipline, Khulna University, Khulna, Bangladesh
2 shared publications - Fairuza Ahmed
Department of Pharmacy, BRAC University, Dhaka, Bangladesh
2 shared publications - Kashfia Nawrin
Department of Chemistry, Graduate School of Science and Technology, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto 860-8555, Japan
2 shared publications - Mohammad Mustakim Billah
Department of Research, Institute for Pharmaceutical Skill Development and Research, Dhaka, Bangladesh
2 shared publications - Abul Hossen
Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh
1 shared publication - Laila Jahan
Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh
1 shared publication
Latest Publications
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 29-36
In vitro assessment of pharmaceutical equivalence and analysis of drug release kinetics of Domperidone 10mg tablets available in Bangladesh market
Background: The aim of this study was to evaluate the pharmaceutical equivalence of different brands of Domperidone tablets marketed in Bangladesh and study their release kinetics model. Methods: Five different brands of Domperidone tablets were purchased from different pharmacies from Dhaka, Bangladesh. The quality control parameters of domperidone tablets were determined by identification, weight variation, disintegration, assay and dissolution tests and the results were compared with USP and BP pharmacopoeia standards. Difference (f1) and similarity (f2) factors were calculated to assess in vitro bioequivalence requirements. Finally, drug release kinetics were studied through model-dependent calculative methods. Results: The results of assay, weight variation and disintegration tests indicated that all samples complied with USP specification limits. The active pharmaceutical ingredients quantitative assay showed that all the brands of domperidone tablets were between the 95% and 105% limit of the label claim met the range of f1 (0-15) and f2 (>50). All brands best fitted in Korsmeyer-Peppas model indicating diffusion mediated release and also shown low AIC in Hixson-Crowell model assuming the release governed by velocity of dissolution. Conclusion: This study revealed that all the domperidone brands met the quality specification of weight variation, disintegration, assay and dissolution. The study also indicated similarity in the dissolution profile of the brands of domperidone tablets with the reference product. Hence, selected generic brands could be substituted with the reference product in clinical practice.
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 29-36
In vitro assessment of pharmaceutical equivalence and analysis of drug release kinetics of Domperidone 10mg tablets available in Bangladesh market
Background: The aim of this study was to evaluate the pharmaceutical equivalence of different brands of Domperidone tablets marketed in Bangladesh and study their release kinetics model. Methods: Five different brands of Domperidone tablets were purchased from different pharmacies from Dhaka, Bangladesh. The quality control parameters of domperidone tablets were determined by identification, weight variation, disintegration, assay and dissolution tests and the results were compared with USP and BP pharmacopoeia standards. Difference (f1) and similarity (f2) factors were calculated to assess in vitro bioequivalence requirements. Finally, drug release kinetics were studied through model-dependent calculative methods. Results: The results of assay, weight variation and disintegration tests indicated that all samples complied with USP specification limits. The active pharmaceutical ingredients quantitative assay showed that all the brands of domperidone tablets were between the 95% and 105% limit of the label claim met the range of f1 (0-15) and f2 (>50). All brands best fitted in Korsmeyer-Peppas model indicating diffusion mediated release and also shown low AIC in Hixson-Crowell model assuming the release governed by velocity of dissolution. Conclusion: This study revealed that all the domperidone brands met the quality specification of weight variation, disintegration, assay and dissolution. The study also indicated similarity in the dissolution profile of the brands of domperidone tablets with the reference product. Hence, selected generic brands could be substituted with the reference product in clinical practice.
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 74-81
Central and peripheral antinociceptive activity of D. linearis ethanolic leaf extract
Background: Dicranopteris linearis, a medicinal plant, is considered effective in relieving pain. Though previously it has been scientifically evaluated, very few of the studies aimed at differentiating the central and peripheral analgesia produced by this plant. The present study was designed to examine the efficacy of its leaf extract in antinociception and qualitatively assess its mode of activity. Methods: Ethanol extract of the leaf at 400, 200 and 100 mg/kg were investigated on mice and compared with the standard(s). Tail flick, tail pressure, tail immersion and hot plate methods were employed to observe central acting potential whereas abdominal constriction and biphasic pain models were executed to understand its peripheral action. Results: DLET 400 mg/kg confirmed moderate efficacy in comparison with the standard morphine in all centrally acting models and superseded (44.29% in formalin treatment, late phase) aspirin in peripherally acting models. Lower doses of the extract were able to produce mild effects in the experiments. Morphine inhibited the tail flick response up to 83.45% at 60-minute interval whereas aspirin exhibited similar efficacy in both writhing (41.06%) and biting (40.35% in late phase) tests. Conclusion: Findings suggested that D. linearis leaf on ethanol extraction yielded in compounds that has potential to suppress nociception. The extract acted more like a peripheral inhibiting agent. However, further investigation is necessary to prescribe its safe and optimum use as an analgesic.
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 74-81
Central and peripheral antinociceptive activity of D. linearis ethanolic leaf extract
Background: Dicranopteris linearis, a medicinal plant, is considered effective in relieving pain. Though previously it has been scientifically evaluated, very few of the studies aimed at differentiating the central and peripheral analgesia produced by this plant. The present study was designed to examine the efficacy of its leaf extract in antinociception and qualitatively assess its mode of activity. Methods: Ethanol extract of the leaf at 400, 200 and 100 mg/kg were investigated on mice and compared with the standard(s). Tail flick, tail pressure, tail immersion and hot plate methods were employed to observe central acting potential whereas abdominal constriction and biphasic pain models were executed to understand its peripheral action. Results: DLET 400 mg/kg confirmed moderate efficacy in comparison with the standard morphine in all centrally acting models and superseded (44.29% in formalin treatment, late phase) aspirin in peripherally acting models. Lower doses of the extract were able to produce mild effects in the experiments. Morphine inhibited the tail flick response up to 83.45% at 60-minute interval whereas aspirin exhibited similar efficacy in both writhing (41.06%) and biting (40.35% in late phase) tests. Conclusion: Findings suggested that D. linearis leaf on ethanol extraction yielded in compounds that has potential to suppress nociception. The extract acted more like a peripheral inhibiting agent. However, further investigation is necessary to prescribe its safe and optimum use as an analgesic.
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 10-18
Protective potential of C. sinensis fruit peel aqueous extract on in vitro inflammation
Background: In different parts of the world, citrus fruit peels are considered potential sources for natural anti-inflammatory agents. The present study was designed to evaluate the anti-inflammatory potential of Citrus. sinensis fruit peel in search for a natural alternative medicine. Methods: In vitro inflammation was modeled through egg albumin denaturation, human erythrocyte membrane destabilization- in hypotonic and thermal conditions; treated with the aqueous peel extract at various concentrations - 31.25, 62.5, 125, 250 and 500 μg/ml and compared with the same concentrations of the reference acetyl salicylic acid (ASA). Half maximal inhibitory concentration (IC50) was determined from the dose-response curve. In addition, phytochemical and physicochemical properties were also assessed. Results: In all experiments, IC50 of the test sample was achieved at higher concentrations (>200 μg/ml). However, in hypotonic and hyperthermic conditions, IC50 was attained at much higher concentrations (>250 μg/ml). ASA showed greater responses in inhibition in comparison to that of the sample. The qualitative phytochemical analysis exhibited that the aqueous extract contained protective components like tannin, phenol, flavonoid, reducing sugar, protein, carbohydrate and steroid. Conclusion: The demonstration of anti-protein denaturation and erythrocyte membrane stabilization indicated a significant potential of the aqueous fruit peel extract as natural anti-inflammatory agent which generated the context for further in-depth investigation.
- 1 April 2021
- Published by Institute for Pharmaceutical Skill Development and Research in Pharmacotherapy and Pharmascience Discovery
- p. 10-18
Protective potential of C. sinensis fruit peel aqueous extract on in vitro inflammation
Background: In different parts of the world, citrus fruit peels are considered potential sources for natural anti-inflammatory agents. The present study was designed to evaluate the anti-inflammatory potential of Citrus. sinensis fruit peel in search for a natural alternative medicine. Methods: In vitro inflammation was modeled through egg albumin denaturation, human erythrocyte membrane destabilization- in hypotonic and thermal conditions; treated with the aqueous peel extract at various concentrations - 31.25, 62.5, 125, 250 and 500 μg/ml and compared with the same concentrations of the reference acetyl salicylic acid (ASA). Half maximal inhibitory concentration (IC50) was determined from the dose-response curve. In addition, phytochemical and physicochemical properties were also assessed. Results: In all experiments, IC50 of the test sample was achieved at higher concentrations (>200 μg/ml). However, in hypotonic and hyperthermic conditions, IC50 was attained at much higher concentrations (>250 μg/ml). ASA showed greater responses in inhibition in comparison to that of the sample. The qualitative phytochemical analysis exhibited that the aqueous extract contained protective components like tannin, phenol, flavonoid, reducing sugar, protein, carbohydrate and steroid. Conclusion: The demonstration of anti-protein denaturation and erythrocyte membrane stabilization indicated a significant potential of the aqueous fruit peel extract as natural anti-inflammatory agent which generated the context for further in-depth investigation.